Global Needle Biopsy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Needle Biopsy Market Size

• The global needle biopsy market size was valued at USD 1.30 billion in 2024 and is expected to reach USD 2.16 billion by 2032, at a CAGR of 6.60% during the forecast period
• The market growth for Needle Biopsy solutions is largely fueled by the rising global incidence of cancer and other chronic diseases requiring definitive diagnosis
• Furthermore, increasing demand for minimally invasive diagnostic procedures, coupled with technological advancements leading to more precise and safer biopsy techniques, is establishing needle biopsy as the modern diagnostic tool of choice. These converging factors are accelerating the uptake of Needle Biopsy solutions, thereby significantly boosting the industry's growth

Needle Biopsy Market Analysis

• Needle biopsy, a minimally invasive procedure for obtaining tissue samples for diagnostic purposes, is increasingly vital in modern healthcare for accurate disease diagnosis and treatment planning in both oncology and other medical fields, due to its precision, reduced patient discomfort, and rapid results
• The escalating demand for needle biopsy is primarily fueled by the widespread rise in cancer incidence, growing preference for less invasive diagnostic methods, and advancements in imaging guidance technologies
• North America dominates the needle biopsy market with the largest revenue share of 36.8% in 2024, characterized by advanced healthcare infrastructure, high incidence of chronic diseases, and a strong presence of key industry players
• Asia-Pacific is expected to be the fastest growing region in the needle biopsy market during the forecast period, with a CAGR of 7.38%, due to increasing healthcare expenditure, rising awareness about early disease diagnosis, and a large patient pool
• The needle-based biopsy guns segment dominates the needle biopsy market with a market share of 62% in 2024, driven by its precise control, accuracy in tissue acquisition, and efficiency in procedures

Report Scope and Needle Biopsy Market Segmentation      

Needle Biopsy Market Trends

“Enhanced Precision and Diagnostics”

• A significant and accelerating trend in the global needle biopsy market is the deepening integration of advanced imaging and pathological analysis workflows. This fusion of technologies is significantly enhancing diagnostic accuracy, procedural efficiency, and ultimately, patient outcomes in tissue sampling
  • For instance, advanced imaging modalities (such as improved ultrasound visibility, real-time CT, and MRI guidance) are being developed to help clinicians more precisely target suspicious lesions during biopsy procedures. Similarly, sophisticated tools are used for the automated analysis of microscopic biopsy slides, improving the speed and accuracy of cancer detection and classification
• Integration in needle biopsy enables features such as learning from vast datasets of pathological images to identify subtle disease patterns, predicting the likelihood of malignancy, and optimizing needle trajectory planning. For instance, some systems improve lesion detection in imaging and can provide intelligent alerts if deviations from the planned biopsy path are detected. Furthermore, advanced image analysis capabilities offer clinicians enhanced confidence in diagnosis, leading to more informed treatment decisions
• This trend towards more intelligent, intuitive, and interconnected biopsy systems is fundamentally reshaping diagnostic expectations in healthcare. Consequently, companies are developing advanced biopsy devices and software with features such as real-time image analysis for guidance and automated pathology interpretations
• The demand for needle biopsy solutions that offer seamless integration of advanced technologies is growing rapidly across healthcare sectors, as clinicians increasingly prioritize precision, efficiency, and comprehensive diagnostic functionality

Needle Biopsy Market Dynamics

Driver

“Growing Need Due to Rising Disease Incidence and Demand for Minimally Invasive Diagnostics”

• The increasing prevalence of diseases, particularly cancer, and the accelerating demand for minimally invasive diagnostic procedures, is a significant driver for the heightened demand for needle biopsy
  • For instance, in May 2024, Cook Medical announced the launch of its next-generation EchoTip AcuCore Endoscopic Ultrasound (EUS) Biopsy Needle. This innovative device is designed to improve precision for biopsying lesions within the gastrointestinal tract, featuring a cobalt-chromium alloy tip for enhanced puncture flexibility and controlled precision. Such advancements in needle design and integration with imaging technologies, including AI-powered imaging and robotic-assisted systems, are expected to significantly drive the needle biopsy market growth in the forecast period by improving diagnostic accuracy, reducing patient discomfort, and enhancing procedural efficiency
• As healthcare providers and patients seek more precise and less traumatic methods for diagnosis, needle biopsy offers advanced features such as image guidance, real-time feedback, and quicker recovery times, providing a compelling upgrade over more invasive surgical biopsies
• Furthermore, the growing focus on early disease detection and personalized medicine is making needle biopsy an integral component of diagnostic pathways, offering seamless integration with other diagnostic tools and treatment planning
• The convenience of outpatient procedures, reduced patient discomfort, and the ability to obtain high-quality tissue samples for accurate diagnosis are key factors propelling the adoption of needle biopsy in both oncology and other medical fields. The increasing availability of user-friendly needle biopsy options further contributes to market growth

Restraint/Challenge

“Concerns Regarding Procedural Risks and High Initial Costs”

• Concerns surrounding the potential risks associated with needle biopsy procedures, including bleeding, infection, and discomfort, pose a significant challenge to broader market penetration. While generally safe, these procedures carry inherent risks that can raise anxieties among potential patients and healthcare providers
  • For instance, high-profile reports of complications or inconclusive results from biopsy procedures can make some patients hesitant to undergo them, potentially delaying diagnosis
• Addressing these concerns through robust training for clinicians, clear patient communication on procedural benefits and risks, and the development of even safer biopsy techniques is crucial for building patient trust. Companies such as those developing advanced imaging guidance emphasize their precision and safety features in their marketing to reassure potential users.
• In addition, the relatively high initial cost of some advanced needle biopsy systems, particularly those with sophisticated imaging or robotic integration, can be a barrier to adoption for price-sensitive healthcare systems, especially in developing regions or for smaller clinics. While basic needle biopsy devices have become more affordable, premium features such as advanced guidance systems or automated tissue processing often come with a higher price tag.
• While prices are gradually decreasing due to technological advancements and economies of scale, the perceived premium for advanced biopsy technology can still hinder widespread adoption, especially for those who do not see an immediate need for the advanced features offered.

Needle Biopsy Market Scope

The market is segmented on the basis of needle type, ergonomics, product, procedure, sample site, utility, application, end user, and distribution channel.

• By Needle Type

On the basis of needle type, the needle biopsy market is segmented into Trephine Biopsy Needles, Klima Sternal Needle, Salah Needle Aspiration Needle, Jamshidi Needle, and Others. The trephine biopsy needles segment dominated the market in 2024. This dominance is attributed to its effectiveness in extracting cylindrical core samples from bone and other dense tissues, crucial for detailed histological analysis.

Trephine Biopsy Needles are also projected to be the fastest-growing segment from 2025 to 2032 in some regional markets, highlighting their increasing adoption and demand for precise tissue samples.

• By Ergonomics

On the basis of ergonomics, the needle biopsy market is segmented into Sharp, Blunt, Quincke, Chiba, Franseen, and Others. The Sharp segment is anticipated to hold the largest market share, driven by its superior precision and ease of penetration, which are crucial for accurate tissue acquisition and minimizing patient discomfort during procedures. While specific market share percentages for ergonomic types globally are not consistently reported, the "Sharp" design's pervasive use in various biopsy needles underscores its dominance.

The Sharp segment is also projected to be the fastest-growing segment in terms of ergonomics, from 2025 to 2032 in regional markets, indicating a consistent demand for efficient and minimally invasive designs.

• By Product

On the basis of product, the needle biopsy market is segmented into fine-needle aspiration biopsy, core needle biopsy, vacuum-assisted biopsy, image-guided biopsy, needle based biopsy guns, and biopsy needles. The needle-based biopsy guns segment dominated the global biopsy needle market in 2024 with a share of 62%. This dominance is attributed to their precise control and efficiency in tissue sampling. The broader

The biopsy needles segment is anticipated to witness the fastest growth from 2025 to 2032, propelled by continuous innovations aimed at enhancing precision and reducing invasiveness.

• By Procedure

On the basis of procedure, the needle biopsy market is segmented into image-guided procedures, ultrasound-guided procedures, stereotactic procedures, CT-guided procedures, MRI-guided procedures, and other procedures. The ultrasound-guided procedures segment held a significant market share in 2024, due to its accuracy, real-time visualization, cost-effectiveness, and safety (absence of ionizing radiation), making it a widely preferred method for guiding biopsies.

• By Sample Site

On the basis of sample site, the needle biopsy market is segmented into Muscles, Bones, and Other Organs (which can include breast, lung, prostate, liver, thyroid, etc.). The other segment dominated the market in 2024, driven by the high incidence of cancers affecting these organs, necessitating frequent biopsies for diagnosis and staging.

The Bones segment is projected to be the fastest-growing segment in terms of sample site, in the forecast period (2025-2032) in some markets, driven by increasing orthopedic diagnoses and bone marrow-related conditions.

• By Utility

On the basis of utility, the needle biopsy market is segmented into disposable and reusable. The disposable segment dominated the market in 2024, due to increased focus on infection control and patient safety in healthcare settings, minimizing the risk of cross-contamination. This segment is also the fastest-growing, with a projected CAGR of 4.34% from 2025 to 2032 in various regional markets, aligning with stringent regulatory guidelines and clinical preferences for single-use instruments.

• By Application

On the basis of application, the needle biopsy market is segmented into Tumour/Cancer, Infection, Inflammation, and Others. The Tumour/Cancer segment accounted for the largest market share in 2024, driven by the rising global incidence of various cancers and the critical role of biopsy in their diagnosis, staging, and treatment planning. This segment is also identified as the fastest-growing segment in the biopsy device market from 2025 to 2032 in some regional studies, reflecting continuous advancements in cancer detection and personalized medicine.

• By End User

On the basis of end user, the needle biopsy market is segmented into hospitals, diagnostic centres, biopsy labs, ambulatory surgical centres, academic and research organizations, and others. The hospitals segment accounted for the largest revenue share in 2024. This dominance stems from their comprehensive infrastructure, advanced diagnostic facilities, and capability to handle complex procedures.

The diagnostic centers segment is projected to register the fastest growth rate, with a CAGR of 7.3% from 2025 to 2032 within the biopsy devices market, driven by the increasing shift towards outpatient procedures and specialized diagnostic services.

• By Distribution Channel

On the basis of distribution channel, the needle biopsy market is segmented into direct tender and retail sales. The direct tender segment dominated the market, representing the largest share in 2024. This channel involves direct procurement by large healthcare institutions, government bodies, and hospital networks, often through bulk purchasing agreements and competitive bidding processes, ensuring consistent supply and better pricing.

This segment is also projected to be the fastest-growing from 2025 to 2032 in some regions, reflecting the expanding healthcare infrastructure and increasing direct purchasing power of large medical facilities.

Needle Biopsy Market Regional Analysis

• North America dominates the Needle Biopsy market with the largest revenue share of 36.8% in 2024, driven by a growing demand for advanced diagnostics and treatment planning, as well as increased awareness of early disease detection
• Healthcare providers and patients in the region highly value the precision, reduced invasiveness, and rapid results offered by needle biopsy procedures, particularly with the integration of advanced imaging and AI in diagnostic pathways
• This widespread adoption is further supported by high disposable incomes, a technologically inclined population readily adopting innovative medical solutions, and the growing preference for remote monitoring and less intensive interventions, establishing needle biopsy as a favored diagnostic tool for various medical conditions, especially cancer

U.S. Needle Biopsy Market Insight

The U.S. needle biopsy market captured the largest revenue share of 41.2% in 2024 within North America, fueled by the swift uptake of advanced diagnostic tools and the expanding trend of minimally invasive procedures. Healthcare providers are increasingly prioritizing the enhancement of diagnostic accuracy through intelligent, precise tissue sampling systems. The growing preference for advanced imaging-guided biopsy setups, combined with robust demand for robotic-assisted procedures and integrated pathology analysis, further propels the needle biopsy industry. Moreover, the increasing integration of cutting-edge medical technologies is significantly contributing to the market's expansion.

Europe Needle Biopsy Market Insight

The Europe needle biopsy market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by stringent healthcare regulations and the escalating need for enhanced diagnostic precision in hospitals and clinics. The increase in chronic disease incidence, coupled with the demand for minimally invasive diagnostic tools, is fostering the adoption of needle biopsies. European healthcare systems are also drawn to the efficiency and improved patient outcomes these procedures offer. The region is experiencing significant growth across various application areas, with needle biopsy being incorporated into both established diagnostic pathways and emerging personalized medicine approaches.

U.K. Needle Biopsy Market Insight

The U.K. needle biopsy market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the escalating focus on early disease diagnosis and a desire for heightened diagnostic accuracy and patient comfort. In addition, concerns regarding disease progression and the importance of timely intervention are encouraging both healthcare providers and patients to choose minimally invasive biopsy solutions. The UK’s embrace of advanced medical technologies, alongside its robust healthcare infrastructure, is expected to continue to stimulate market growth.

Germany Needle Biopsy Market Insight

The Germany needle biopsy market is expected to expand at a considerable CAGR during the forecast period fueled by increasing awareness of precision diagnostics and the demand for technologically advanced solutions. Germany’s well-developed healthcare infrastructure, combined with its emphasis on innovation and high-quality patient care, promotes the adoption of needle biopsies, particularly in oncology and specialized diagnostic centers. The integration of needle biopsy with advanced imaging systems is also becoming increasingly prevalent, with a strong preference for secure, accurate, and high-quality diagnostic solutions aligning with local healthcare expectations.

Asia-Pacific Needle Biopsy Market Insight

The Asia-Pacific needle biopsy market is poised to grow at the fastest CAGR of 7.38% to 10.3% during the forecast period of 2025 to 2032, driven by increasing urbanization, rising disposable incomes, and technological advancements in countries such as China, Japan, and India. The region's growing inclination towards advanced medical diagnostics, supported by government initiatives promoting healthcare infrastructure development, is driving the adoption of needle biopsies. Furthermore, as APAC emerges as a manufacturing hub for medical devices, the affordability and accessibility of needle biopsy options are expanding to a wider patient base.

Japan Needle Biopsy Market Insight

The Japan needle biopsy market is gaining momentum due to the country’s high-tech culture, rapid urbanization, and demand for efficient diagnostic procedures. The Japanese market places a significant emphasis on precise diagnosis and early intervention, and the adoption of needle biopsies is driven by the increasing number of cancer cases and chronic diseases. The integration of needle biopsies with other advanced medical technologies, such as diagnostic imaging and pathology systems, is fueling growth. Moreover, Japan's aging population is likely to spur demand for accurate, less invasive diagnostic solutions in both hospital and outpatient settings.

China Needle Biopsy Market Insight

The China needle biopsy market accounted for the largest market revenue share in Asia Pacific in 2024, attributed to the country's expanding middle class, rapid urbanization, and high rates of technological adoption. China stands as one of the largest markets for medical devices, and needle biopsies are becoming increasingly popular in hospitals, diagnostic centers, and specialized clinics. The push towards improved healthcare access and the availability of affordable needle biopsy options, alongside strong domestic manufacturers, are key factors propelling the market in China.

Needle Biopsy Market Share

The needle biopsy industry is primarily led by well-established companies, including:

• MEDAX S.R.L. Unipersonale (Italy)
• Boston Scientific Corporation (U.S.)
• Cook Group (U.S.)
• Hologic, Inc. (U.S.)
• St. Stone Medical (India)
• AprioMed AB (Sweden)
• AMECATH (Egypt)
• ZAMAR CARE (Croatia)
• Cardinal Health (U.S.)
• INRAD, Inc. (U.S.)
• BD (U.S.)
• MÖLLER Medical GmbH (Germany)
• HAKKO CO.,LTD. (Japan)
• Argon Medical Devices (U.S.)
• Merit Medical Systems (U.S.)
• weLLgo Medical Products GmbH (Germany)
• Swastik Enterprise (India)
• Tsunami Medical (Italy)
• PAJUNK (Germany)
• B. Braun SE (Germany)

Latest Developments in Global Needle Biopsy Market

• In September 2023, Insight Medbotics The FDA granted 510(k) clearance for the IGAR system, a robotic guidance and placement system compatible with MRI, specifically engineered for breast biopsy procedures. This advancement highlights Insight Medbotics' commitment to developing cutting-edge technologies that enhance precision and diagnostic outcomes in challenging biopsy scenarios, ensuring greater accuracy and patient safety
• In June 2023, Medtronic plc, Medtronic introduced the Bioprobe Precision biopsy needle system, specifically designed for lung and liver biopsies. This innovative system underscores Medtronic's dedication to delivering advanced, reliable tools that improve tissue sampling accuracy and procedural efficiency in critical internal organ biopsies, reinforcing its position in the rapidly evolving global needle biopsy market
• In May 2023, Argon Medical Devices launched the SuperCore Advantage, a new semi-automatic biopsy instrument for the U.S. market. This device is engineered to provide a superior volume of tissue samples for soft tissue biopsies, which may increase the likelihood of accurate diagnosis. This development highlights Argon Medical's commitment to enhancing diagnostic confidence and patient outcomes through improved sample quality
• In April 2023, BD acquired Velano Vascular, a strategic move aimed at enhancing its biopsy needle portfolio. This acquisition underscores BD's dedication to delivering innovative, reliable access solutions that improve patient experience and expand its offerings in the global needle biopsy market
• In May 2024, Cook Medical announced the launch of the next-generation EchoTip AcuCore Endoscopic Ultrasound (EUS) Biopsy Needle. This needle is designed to improve precision for biopsying lesions within the gastrointestinal tract, showcasing Cook Medical's commitment to advancing minimally invasive diagnostic capabilities
• In November 2024, Mammotome introduced the Mammotome AutoCore Single Insertion Core Biopsy System, the first automated spring-loaded core needle biopsy system to be launched in the marketplace. This new product launch signifies Mammotome's continued dedication to furthering breast biopsy technology and optimizing patient care results through increased efficiency

SKU-36643